Fred Hutchinson grants Mustang rights to CD20-specific CAR T

Fred Hutchinson Cancer Research Center (Seattle, Wash.) granted the Mustang Bio Inc. (NASDAQ:MBIO) subsidiary of Fortress Biotech Inc. (NASDAQ:FBIO) exclusive, worldwide rights to a third-generation CD20-specific chimeric antigen receptor (CAR) T therapy that incorporates tumor necrosis factor (TNF) receptor superfamily member 9 (4-1BB; TNFRSF9; CD137) and CD28 co-stimulatory domains. Mustang will partially fund a Phase I/II trial to evaluate the candidate in patients with relapsed or refractory B cell non-Hodgkin’s lymphoma (NHL). The trial is expected to begin at the center next quarter...